论文部分内容阅读
目的:研究唑来膦酸联合化疗的治疗方法对于晚期非小细胞肺癌骨转移的临床疗效。方法:将我院2000年7月到2011年7月收治的24例晚期非小细胞肺癌骨转移患者随机分为观察组、对照组两组。观察组13例,采用唑来膦酸联合化疗的治疗方式进行治疗;对照组组11例,只采用化疗进行治疗。观察组、对照组两组患者采用的化疗方案相同。结果:观察组疼痛总缓解率91.0%,对照组有效率63.6%,治疗组总体疗效优于对照组,P<0.05,两组不良反应相似,无差别。结论:用唑来膦酸联合化疗治疗方法治疗晚期非小细胞肺癌的骨转移,其疗效较好,值得临床上的推广。
OBJECTIVE: To study the clinical efficacy of zoledronic acid combined with chemotherapy in the treatment of bone metastases from advanced non-small cell lung cancer. Methods: Twenty-four patients with bone metastases from advanced non-small cell lung cancer who were admitted to our hospital from July 2000 to July 2011 were randomly divided into observation group and control group. Thirteen patients in the observation group were treated with zoledronic acid combined with chemotherapy; 11 patients in the control group were treated with chemotherapy alone. The observation group and the control group had the same chemotherapy regimen. Results: The total pain remission rate was 91.0% in the observation group and 63.6% in the control group. The overall curative effect in the treatment group was better than that in the control group, P<0.05. The adverse reactions in the two groups were similar and there was no difference. Conclusion: The treatment of bone metastasis of advanced non-small cell lung cancer with zoledronic acid combined with chemotherapy has good curative effect and is worthy of clinical promotion.